Early Results of First Trial Conducted Exclusively in People with Pre-Extensively Drug-Resistant Tuberculosis Show Promise
August 1, 2025Paris/Boston, 13 November 2024 - The endTB consortium has completed endTB-Q, the first Phase 3 randomized controlled trial to exclusively enroll people suffering from pre-extensively drug-resistant tuberculosis (pre-XDR-TB), a very hard-to-treat form of tuberculosis (TB). The trial, conducted by the endTB...
read more
